1. Home
  2. RVPH vs DTSQ Comparison

RVPH vs DTSQ Comparison

Compare RVPH & DTSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • DTSQ
  • Stock Information
  • Founded
  • RVPH 2006
  • DTSQ 2022
  • Country
  • RVPH United States
  • DTSQ United States
  • Employees
  • RVPH N/A
  • DTSQ N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • DTSQ
  • Sector
  • RVPH Health Care
  • DTSQ
  • Exchange
  • RVPH Nasdaq
  • DTSQ NYSE
  • Market Cap
  • RVPH 32.8M
  • DTSQ 91.7M
  • IPO Year
  • RVPH N/A
  • DTSQ 2024
  • Fundamental
  • Price
  • RVPH $0.40
  • DTSQ $10.39
  • Analyst Decision
  • RVPH Strong Buy
  • DTSQ
  • Analyst Count
  • RVPH 5
  • DTSQ 0
  • Target Price
  • RVPH $9.00
  • DTSQ N/A
  • AVG Volume (30 Days)
  • RVPH 3.4M
  • DTSQ 531.0
  • Earning Date
  • RVPH 08-13-2025
  • DTSQ 01-01-0001
  • Dividend Yield
  • RVPH N/A
  • DTSQ N/A
  • EPS Growth
  • RVPH N/A
  • DTSQ N/A
  • EPS
  • RVPH N/A
  • DTSQ 0.28
  • Revenue
  • RVPH N/A
  • DTSQ N/A
  • Revenue This Year
  • RVPH N/A
  • DTSQ N/A
  • Revenue Next Year
  • RVPH N/A
  • DTSQ N/A
  • P/E Ratio
  • RVPH N/A
  • DTSQ $37.07
  • Revenue Growth
  • RVPH N/A
  • DTSQ N/A
  • 52 Week Low
  • RVPH $0.30
  • DTSQ $9.96
  • 52 Week High
  • RVPH $4.28
  • DTSQ $10.49
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 33.44
  • DTSQ N/A
  • Support Level
  • RVPH $0.35
  • DTSQ N/A
  • Resistance Level
  • RVPH $0.83
  • DTSQ N/A
  • Average True Range (ATR)
  • RVPH 0.06
  • DTSQ 0.00
  • MACD
  • RVPH -0.01
  • DTSQ 0.00
  • Stochastic Oscillator
  • RVPH 17.36
  • DTSQ 0.00

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

About DTSQ DT CLOUD STAR ACQUISITION CORP

DT Cloud Star Acquisition Corp is a blank check company.

Share on Social Networks: